Quantcast
Environmental News for a Healthier Planet and Life

Monsanto Faces Rejection in U.S. Over GMO Soybean

Food

Monsanto, the controversial biotech seed giant, keeps running into trouble on the lucrative GMO soybean market this year.

Although 94 percent of U.S. soybean crops come from genetically modified seeds, Monsanto's latest offering isn't meeting with the approval of grain traders in the U.S. Called “Roundup Ready 2 Xtend," the Wall Street Journal reported on May 2 that major grain corporations like Archer Daniels Midland Co. and Cargill Inc. are rejecting the soybean because it lacks important regulatory approval in the European Union and could disrupt international trade.

Activists raise public awareness about the consequences of using Monsanto herbicides in Argentina. Photo credit: Pedro Jesus Galvani / Eco- Network

“The grain companies' stance is a potential blow to a product that Monsanto has touted as a blockbuster for U.S. farm fields," wrote Jacob Bunge.

Trade groups for the grain companies attacked Monsanto for attempting to sell the seeds without obtaining EU approval first. “Monsanto's actions with respect to RR2X soybeans are an unacceptable and very troubling development and we urge that it not be repeated," the groups wrote in a letter quoted by the Journal.

According to the Journal:

“The letter comes after Bunge [Ltd., a food company], Archer Daniels Midland and Louis Dreyfus Co. recently notified farmers that their U.S. facilities wouldn't buy soybeans grown from seeds that contain Monsanto's new crop genes. The companies sent letters and posted signs at grain elevators."

Soybean planting began early this month and farmers could be out of luck if Monsanto is unable to obtain the necessary approvals before the fall harvest.

Trade groups are understandably nervous about unapproved genetic components since China began rejecting shipments of genetically-modified corn in 2013, causing grain traders to lose hundreds of millions of dollars.

The setback in U.S. markets comes as Monsanto continues its years-long battle to collect royalties in Argentina, where farmers frequently plant seeds harvested from previous crops rather than pay for new seeds each year.

Although the former method represents an ancient agricultural tradition, Monsanto's lawyers argue that international law enables its representatives to collect payments from any farm where genetic testing found crops containing the company's patented genes from its Intacta brand soybean.

Bloomberg reported on Saturday that the corporation “was expecting to collect royalties for about 15 percent of this season's Argentine soybean crop, which is forecast by the Buenos Aires Grains Exchange to be 56 million metric tons."

But the Argentine government would have to first approve the Intacta patent, a process which they now claim could take months. Argentina's science and technology minister, Lino Baranao, told Bloomberg:

“The Monsanto issue is very distinctive as Argentina still hasn't granted the company a patent for Intacta … A final decision must emerge soon, but I am not sure this will happen for the 2015-16 crop. We have asked the Institute for Property Rights to speed up the process, but it may take months."

The government also declined to use Monsanto's genetic testing labs, insisting on instead using labs approved by the Agriculture Ministry.

It's the latest round of maneuvering between the government and the agribusiness giant since Argentina requested in April that Monsanto waive its royalty requirements.

“Monsanto rejected that waiver without comment, but agreed to cut the royalties from the equivalent of fifteen dollars per hectare to some nine dollars per hectare, for growers who use Monsanto technology but who do not purchase seeds directly from the corporation," Sputnik News reported.

YOU MIGHT ALSO LIKE

Does Glyphosate Cause Cancer?

'Mistaken' Release of Glyphosate Report Raises Questions Over EPA's Ties to Monsanto

Big Ag Forces Firing of Long-Time Farm News Cartoonist

3 Easy Steps to Make Cold Brew Coffee at Home

EcoWatch Daily Newsletter

The outside of the Food and Drug Administration headquarters in White Oak, Md. on Nov. 9, 2015. Al Drago / CQ Roll Call

The U.S. Food and Drug Administration has approved the use of two malarial drugs to treat and prevent COVID-19, the respiratory infection caused by the SARS-CoV-2 coronavirus, despite only anecdotal evidence that either is proven effective in treating or slowing the progression of the disease in seriously ill patients.

Read More Show Less
Some speculate that the dissemination of the Antarctic beeches or Nothofagus moorei (seen above in Australia) dates to the time when Antarctica, Australia and South America were connected. Auscape / Universal Images Group / Getty Images

A team of scientists drilled into the ground near the South Pole to discover forest and fossils from the Cretaceous nearly 90 million years ago, which is the time when dinosaurs roamed the Earth, as the BBC reported.

Read More Show Less
Sponsored
The recovery of elephant seals is one of the "signs of hope" that scientists say show the oceans can recover swiftly if we let them. NOAA / CC BY 2.0

The challenges facing the world's oceans are well known: plastic pollution could crowd out fish by 2050, and the climate crisis could wipe out coral reefs by 2100.

Read More Show Less
A schoolchildren crossing sign is seen in front of burned trees in Mallacoota, Australia on Jan. 15, 2020. Luis Ascui / Getty Images

By Bhiamie Williamson, Francis Markham and Jessica Weir

The catastrophic bushfire season is officially over, but governments, agencies and communities have failed to recognize the specific and disproportionate impact the fires have had on Aboriginal peoples.

Read More Show Less
Workers convert the Scottish Events Campus, where COP26 was to be held, into a field hospital to treat COVID-19 patients. ANDY BUCHANAN / AFP via Getty Images

The most important international climate talks since the Paris agreement was reached in 2015 have been delayed because of the coronavirus pandemic.

Read More Show Less